دورية أكاديمية
Prostate cancer immunotherapy.
| العنوان: | Prostate cancer immunotherapy. |
|---|---|
| المؤلفون: | May KF Jr; Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA. kmay1@partners.org, Gulley JL, Drake CG, Dranoff G, Kantoff PW |
| المصدر: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2011 Aug 15; Vol. 17 (16), pp. 5233-8. Date of Electronic Publication: 2011 Jun 23. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Denville, NJ : The Association, c1995- |
| مواضيع طبية MeSH: | Cancer Vaccines/*therapeutic use , Immunotherapy/*methods , Prostatic Neoplasms/*immunology , Prostatic Neoplasms/*therapy, Animals ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/therapeutic use ; CTLA-4 Antigen/immunology ; CTLA-4 Antigen/metabolism ; Clinical Trials as Topic ; Disease Models, Animal ; Humans ; Immunotherapy/trends ; Ipilimumab ; Male ; Mice ; Models, Immunological ; Programmed Cell Death 1 Receptor/immunology ; Programmed Cell Death 1 Receptor/metabolism ; Prostatic Neoplasms/metabolism ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Tissue Extracts/therapeutic use |
| مستخلص: | The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U.S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies, exemplified by sipuleucel-T and PROSTVAC-VF, and immune checkpoint blockade of CTLA-4 and PD-1. Improved understanding of the immune responses generated by these strategies and development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide building blocks for future immunotherapies. (©2011 AACR.) |
| References: | Int Immunol. 2005 Feb;17(2):133-44. (PMID: 15611321) Prostate. 2009 Nov 1;69(15):1694-703. (PMID: 19670224) Clin Cancer Res. 2011 Feb 15;17(4):907-17. (PMID: 21106727) Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70. (PMID: 11734652) Nat Rev Immunol. 2006 Oct;6(10):715-27. (PMID: 16977338) J Clin Oncol. 2010 Jul 1;28(19):3167-75. (PMID: 20516446) Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10. (PMID: 18287062) Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103. (PMID: 9223321) J Immunol. 2004 Nov 15;173(10):6098-108. (PMID: 15528346) Science. 2001 Jan 12;291(5502):319-22. (PMID: 11209085) Nat Rev Cancer. 2007 Apr;7(4):256-69. (PMID: 17384581) J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. (PMID: 20826737) Front Biosci. 2007 Sep 01;12:4957-71. (PMID: 17569623) Cancer Res. 2000 May 1;60(9):2444-8. (PMID: 10811122) J Clin Oncol. 2006 Jul 1;24(19):3089-94. (PMID: 16809734) Clin Cancer Res. 2007 Mar 15;13(6):1810-5. (PMID: 17363537) Immunity. 1995 Nov;3(5):541-7. (PMID: 7584144) Clin Cancer Res. 2007 Dec 1;13(23):6947-58. (PMID: 18056169) N Engl J Med. 2010 Aug 19;363(8):711-23. (PMID: 20525992) Annu Rev Immunol. 2008;26:677-704. (PMID: 18173375) Blood. 2009 Aug 20;114(8):1537-44. (PMID: 19423728) Clin Cancer Res. 2008 Jun 1;14(11):3254-61. (PMID: 18519750) Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17174-9. (PMID: 15569934) J Immunol. 2006 Nov 15;177(10):7398-405. (PMID: 17082659) Immunity. 1999 Aug;11(2):141-51. (PMID: 10485649) Blood. 2008 Aug 15;112(4):1175-83. (PMID: 18523152) Science. 1995 Nov 10;270(5238):985-8. (PMID: 7481803) J Exp Med. 2005 Apr 18;201(8):1257-68. (PMID: 15824085) Nat Med. 2003 May;9(5):562-7. (PMID: 12704383) J Immunol. 2007 Feb 1;178(3):1268-76. (PMID: 17237372) Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15074-9. (PMID: 10611340) J Clin Oncol. 2010 Mar 1;28(7):1099-105. (PMID: 20100959) Cancer Immunol Immunother. 2010 May;59(5):663-74. (PMID: 19890632) Cancer Res. 2009 Jan 15;69(2):609-15. (PMID: 19147575) Cancer Cell. 2005 Mar;7(3):239-49. (PMID: 15766662) Prostate. 2008 Jan 1;68(1):1-10. (PMID: 17948280) J Immunol. 2009 Oct 15;183(8):4848-52. (PMID: 19801511) Clin Cancer Res. 2009 Dec 1;15(23):7412-20. (PMID: 19934295) Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13003-8. (PMID: 18723683) Nat Rev Immunol. 2010 Aug;10(8):580-93. (PMID: 20651745) J Immunol Methods. 2009 Aug 31;348(1-2):9-17. (PMID: 19552894) Nat Rev Cancer. 2006 Jan;6(1):24-37. (PMID: 16397525) J Exp Med. 2009 Aug 3;206(8):1717-25. (PMID: 19581407) N Engl J Med. 2010 Jul 29;363(5):411-22. (PMID: 20818862) Cancer Res. 2005 Feb 1;65(3):1089-96. (PMID: 15705911) Clin Cancer Res. 2008 Jul 15;14(14):4526-31. (PMID: 18628467) Eur J Cancer. 2009 Jun;45(9):1664-72. (PMID: 19318244) J Immunol. 2005 Aug 15;175(4):2741-53. (PMID: 16081852) |
| معلومات مُعتمدة: | CA143083 United States CA NCI NIH HHS; 5P01CA089021-10 United States CA NCI NIH HHS; CA78378 United States CA NCI NIH HHS; R01 CA143083-03 United States CA NCI NIH HHS; R01 CA127153-05 United States CA NCI NIH HHS; P01 CA089021 United States CA NCI NIH HHS; 1P50CA58236-15 United States CA NCI NIH HHS; ZIA BC010666-06 United States Intramural NIH HHS; P50 CA090381 United States CA NCI NIH HHS; P01 CA078378-13 United States CA NCI NIH HHS; P01 CA089021-10 United States CA NCI NIH HHS; P50 CA058236 United States CA NCI NIH HHS; P50 CA058236-15 United States CA NCI NIH HHS; P30 CA006973 United States CA NCI NIH HHS; P01 CA078378 United States CA NCI NIH HHS; P50 CA090381-09 United States CA NCI NIH HHS; R01 CA127153 United States CA NCI NIH HHS; R01 CA143083 United States CA NCI NIH HHS; 5P50CA090381-09 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Antineoplastic Agents) 0 (CTLA-4 Antigen) 0 (Cancer Vaccines) 0 (Ipilimumab) 0 (Programmed Cell Death 1 Receptor) 0 (Tissue Extracts) 8Q622VDR18 (sipuleucel-T) |
| تواريخ الأحداث: | Date Created: 20110625 Date Completed: 20120203 Latest Revision: 20240404 |
| رمز التحديث: | 20240404 |
| مُعرف محوري في PubMed: | PMC3263933 |
| DOI: | 10.1158/1078-0432.CCR-10-3402 |
| PMID: | 21700764 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-3265 |
|---|---|
| DOI: | 10.1158/1078-0432.CCR-10-3402 |